REED ELIZABETH E 4
4 · Travere Therapeutics, Inc. · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) Chief Legal Officer Elizabeth E. Reed Sells Shares
What Happened
Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics (TVTX), sold a total of 2,994 shares in two open‑market transactions on February 4, 2026. She sold 2,485 shares at an average reported price of $32.07 (proceeds $79,694) and 509 shares at an average reported price of $32.74 (proceeds $16,665), for combined proceeds of roughly $96,359. These were sales (not purchases) and appear to include shares sold to cover tax obligations from RSU vesting.
Key Details
- Transaction date: February 4, 2026; Form 4 filed February 5, 2026 (appears timely).
- Lots: 2,485 shares @ weighted avg $32.07 (price range $31.63–$32.61); 509 shares @ weighted avg $32.74 (price range $32.64–$32.90).
- Total shares sold: 2,994; total reported proceeds ≈ $96,359.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes: Sale made pursuant to a written 10b5‑1 trading plan (adopted June 16, 2025) and includes shares sold to cover tax withholding from RSU vesting. Full breakdown of shares sold at each price is available upon request (per filing footnotes).
- Transaction type code: S = Sale.
Context
Sales executed under a 10b5‑1 plan are typically pre‑scheduled and can be used for routine needs (including tax withholding on vested awards); they do not by themselves indicate management sentiment about the company. For retail investors, purchases by insiders are often considered more informative about confidence than routine, plan‑driven sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-04$32.07/sh−2,485$79,694→ 105,720 total - Sale
Common Stock
[F1][F3]2026-02-04$32.74/sh−509$16,665→ 105,211 total
Footnotes (3)
- [F1]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F2]The weighted average sale price for the transaction reported was $32.07, and the range of prices were between $31.63 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of theIssuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The weighted average sale price for the transaction reported was $32.74, and the range of prices were between $32.64 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.